Table 1.
Baseline characteristics of solid organ transplant recipients and matched controls after third dose of a SARS-CoV-2 mRNA vaccine.
| Baseline characteristics | SOT recipients (n=420)Median (IQR) or n (%) | Controls (n=840)Median (IQR) or n (%) |
|---|---|---|
| Demographics | ||
| Age | 57.2 (47.7-66.3) | 60 (51-69) |
| Sex (males) | 253 (60.2) | 506 (60.2) |
| Comorbidities | ||
| Organ transplantation | 420 (100) | – |
| Diabetes Mellitus | 86 (20.5) | 46 (5.5) |
| Cancer | 28 (6.7) | 57 (6.8) |
| Peripheral vascular disease | 25 (6.0) | 8 (1) |
| Chronic pulmonary diseaseb | 20 (4.8) | 38 (4.5) |
| Heart diseasea | 19 (4.5) | 30 (3.6) |
| Renal diseased | 17 (4.1) | 6 (0.7) |
| Cerebrovascular disease | 15 (3.6) | 20 (2.4) |
| Rheumatic disease | 12 (2.9) | 12 (1.4) |
| Liver diseasec | 11 (2.6) | 13 (1.6) |
| Type of transplant | ||
| Kidney Liver |
311 (74.1) 68 (16.2) |
– |
| Heart | 18 (4.3) | – |
| Lung | 16 (3.8) | – |
| Combined | 7 (1.7) | – |
| Immunosuppressive treatment | ||
| Prednisolone | 97 (23) | Lacking data |
| CNIe | 331 (79) | – |
| Proliferation inhibitorf | 388 (92) | – |
aHeart transplants excluded. bLung transplants excluded. cLiver transplants excluded. dKidney transplants excluded eCalcineurin inhibitor (CNI): tacrolimus and cyclosporine. fProliferation inhibitors: mycophenolate and azathioprine.